Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion takes over Enobia
Enobia develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders. Goldman, Sachs & Co. acted as financial advisor to Alexion. Ropes and Gray LLP acted
Enobia develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders. Goldman, Sachs & Co. acted as financial advisor to Alexion. Ropes and Gray LLP acted
The financial details of the agreement have not been disclosed. The product is based on the Gibson Assembly method. Gibson Assembly uses a one-step, isothermal approach to enable
Prismic has also secured Scarista’s exclusive license from Amarin Neuroscience to develop, market, and out-license patents covering highly purified forms of omega-3 fatty acids for the treatment of
Based on this review classification, the FDA has issued an action date for the NDA of 5 June 2012 under the Prescription Drug User Fee Act (PDUFA). Salix
Under the agreement, the cross-royalty rates were reduced and commercial rights for certain territories were changed. Sobi will have commercial rights in Europe, Russia, Turkey and certain countries
Liposomal Grb-2 is indicated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
Mylan has acquired the abbreviated new drug application (ANDA) of the generic version of Valeant’s BenzaClin, Clindamycin Phosphate / Benzoyl Peroxide Gel. Mylan also has purchased a license
Vorapaxar, an investigational oral Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist, is being developed for the prevention of thrombosis, thereby reducing cardiovascular death (CVD). TRA-2P study demonstrated
The approval is backed by results from a randomized withdrawal study designed to assess the efficacy of Vyvanse in adults aged 18 to 55 years who were receiving
XanoLean, a nutrient-rich, botanical formula works as a appetite suppressant producing a completely satisfied feeling while eating less food, the company said. The natural product does not produce